Search in the Abstract Database

Search Abstracts 2012

* = Presenting author

P301. Short-term effectiveness and impact on quality of life of iron carboxymaltose in the treatment of iron deficiency anemia associated with inflammatory bowel disease


M.P. Soto-Escribano1, V. García Sánchez1, E. Iglesias Flores2, J.M. Benítez-Cantero1, Á. González-Galilea1, F. Gómez Camacho1

1Reina Sofia Hospital, Digestive Unit, Cordoba, Spain; 2Reina Sofia Hospital, Cordoba, Spain



Background: Iron carboxylmaltose (FeCM) has proved effective and safe in the treatment of iron deficiency anemia, but there are few data on short-term efficacy and the impact on quality of life (QoL) in patients with inflammatory bowel disease (IBD). Therefore, the objectives of this study were to describe the response to treatment with FeCM assessing their short-term efficacy, safety and impact on QoL in patients with IBD and iron deficiency anemia, and to identify possible predictors of therapeutic response.

Methods: We included 30 patients with IBD and iron deficiency anemia who were treated with FeCM during the months of May 2010 and May 2011. We collected clinical and laboratory variables at baseline and one month after treatment. The disease activity was assessed by Truelove-Witts index in ulcerative colitis (UC) and the Harvey–Bradshaw in Crohn's disease (CD). Response was assessed at one month, considering therapeutic response the rise of >2 g/dl baseline hemoglobin (Hb). The impact on QoL was assessed using the questionnaire IBDQ‑9 before and one month after treatment. Side effects were recorded by telephone survey at week of the infusion.

Results: The mean age was 38.6 years (±14.3) and 66.7% (20) were women. 63.3% (19) of patients had CD and 36.7% had UC. The mean disease duration was 82.5 months (±86). At baseline, 60% were in remission or with mild clinical activity. The mean Hb level at baseline was 9.9 g/dl (±0.9) and one month after treatment was 12.2 g/dl (±1.1). The global average rise after treatment was 2.2 g/dl (95% CI 2.7–1.8 p < 0.05) and the overall response was 80% (24). The questionnaires IBDQ‑9 pre-and post-treatment showed a significant improvement on QoL with an average difference of 6.1 (95% CI 8.6–3.5 p < 0.05). Side effects appeared in 13.3% (4), all of them were mild. Predictors of response to treatment were not identified.

Conclusions: The FeCM is effective and safe in the treatment of iron deficiency anemia associated with IBD reaching a early response and improving the QoL of patients.